# Can Oral Mucosal Delivery Unlock Cannabinoid Medicine’s Potential? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/oral-mucosal-cannabinoid-absorption-potential/ > **Published:** 2026-04-30T01:03:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:56:34-04:00 > **Clinical Summary:** Explore oral mucosal cannabinoid absorption as a promising method to improve bioavailability and therapeutic effects of cannabinoid medicines. --- By **[Dr. Benjamin Caplan](https://cedclinic.com/cannabis-halloween-safety/), MD**  |  Board-Certified Family Physician, CMO at CED Clinic  |  Evidence Watch Clinical Insight | CED Clinic When cannabinoids like THC and CBD are swallowed, the liver destroys most of the dose before it ever reaches the bloodstream. A new formulation science review explores how absorbing cannabinoids through the cheek or under the tongue could dramatically improve how much medicine actually gets through, though none of these newer approaches have been validated in large [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) yet. A new narrative review published in AAPS PharmSciTech maps the formulation science landscape for moving cannabinoids from conventional edibles and smoking into stable, precise mucosal drug products, cataloguing films, gels, mucoadhesive matrices, and advanced fabrication methods that could bypass the liver and improve cannabinoid bioavailability. CED Clinical Relevance #72 Strong Clinical Relevance Directly addresses a core challenge in cannabinoid prescribing, though the evidence base remains preclinical and the review generates no original data. Cannabinoid Pharmacokinetics Drug Formulation Oral Mucosal Delivery Bioavailability Permeation Enhancement Why This Matters Clinicians who prescribe cannabinoid medicines routinely confront a frustrating pharmacokinetic reality: oral CBD and THC bioavailability hovers between 6 and 19 percent, meaning most of the administered dose never reaches its target. Inhaled delivery improves absorption but introduces pulmonary toxicity risks and dose unpredictability. The only approved oromucosal product, Sativex, has well-documented limitations including mucosal irritation and inadvertent swallowing. Understanding what formulation innovations are on the horizon is critical for any clinician advising patients on [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/), because better delivery platforms could fundamentally reshape dosing precision and therapeutic reliability. Clinical Summary Cannabinoids have demonstrated pharmacological activity across pain, spasticity, epilepsy, and nausea indications, yet their clinical utility is consistently undermined by poor bioavailability when administered orally. THC and CBD are both highly lipophilic, undergo extensive first-pass hepatic metabolism via cytochrome P450 enzymes, and degrade in the gastrointestinal tract. These factors produce systemic availability of roughly 6 to 10 percent for THC and 6 to 19 percent for CBD after oral ingestion, compared with approximately 31 percent via inhalation. Oral mucosal delivery, specifically through the buccal (cheek) and sublingual (under the tongue) routes, offers a mechanistically attractive alternative because these tissues are richly vascularized and drain directly into systemic circulation, largely bypassing hepatic first-pass metabolism. This narrative review catalogues the formulation strategies most likely to exploit these anatomical advantages, including fast-dissolving sublingual films, mucoadhesive buccal matrices, in situ gels, lipid-based particulate carriers, and permeation enhancers such as terpenes. The authors highlight that buccal and sublingual tissues differ substantially in epithelial thickness and permeability, demanding distinct product design approaches. Advanced fabrication methods such as hot melt extrusion and 3D printing are discussed as routes toward personalized dosing. Importantly, the review generates no original experimental data and does not employ systematic search methods. All conclusions are literature-synthesis-level, and the authors acknowledge that clinical validation of these novel dosage forms remains an unmet need. Dr. Caplan’s Take This review gets something fundamentally right that is often overlooked in cannabinoid conversations: the delivery method is not a trivial detail. It is, in many cases, the single largest variable determining whether a patient gets a therapeutic dose or essentially wastes their medicine. The formulation science described here is genuinely promising, and the physiological rationale for buccal and sublingual routes is sound. But I want to be honest about the distance between bench-side innovation and bedside reality. Nearly every formulation discussed here lacks rigorous human pharmacokinetic data, and the review itself does not include systematic search methods, so we cannot be certain the literature was surveyed comprehensively. In my practice, I already counsel patients to use sublingual tinctures and hold them under the tongue for at least 60 to 90 seconds precisely because bypassing the liver makes a meaningful difference. I see patients who switched from edibles to sublingual administration and noticed improved consistency in their response. This review reinforces that clinical observation with mechanistic clarity, and it gives me confidence that the field is moving toward better products. But I am not ready to tell patients that any of the novel dosage forms described here are available or proven. We are watching the science develop, and that is worth tracking closely. Clinical Perspective This review sits at an important inflection point in [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/). We have a growing number of approved and off-label cannabinoid indications, a single approved oromucosal product with known shortcomings, and a robust preclinical formulation pipeline that has not yet been pressure-tested through phase II or III trials. For clinicians, the practical value of this review lies in understanding why current delivery methods underperform and which emerging approaches have the strongest mechanistic basis. It does not, however, provide evidence that any specific novel formulation improves clinical outcomes over existing products. Pharmacologically, clinicians should note that bypassing first-pass metabolism changes more than just bioavailability: it also alters the metabolite profile. THC metabolized hepatically produces 11-hydroxy-THC, which is psychoactive and may contribute to adverse effects at unpredictable levels. Mucosal absorption that avoids this pathway could, in theory, produce a more predictable psychoactive profile, though this has not been confirmed in controlled trials. Drug interaction considerations remain relevant, as CYP3A4 and CYP2C19 activity still [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Can Mouth-Dissolving Films and Gels Solve Cannabis Medicine’s Bioavailability Problem?](https://cedclinic.com/oral-mucosal-cannabinoid-bioavailability-review/) Explore how innovative films and gels may enhance [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) bioavailability through oral mucosal delivery. [Read More](https://cedclinic.com/oral-mucosal-cannabinoid-bioavailability-review/) [Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed](https://cedclinic.com/cannabinoid-oral-mucosal-delivery-formulation-fabrication/) A detailed review of formulation and fabrication methods for cannabinoid oral mucosal delivery. [Explore Details](https://cedclinic.com/cannabinoid-oral-mucosal-delivery-formulation-fabrication/) [Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.](https://cedclinic.com/oral-cannabinoid-bioavailability-delivery-absorption/) Comprehensive insights into enhancing cannabinoid bioavailability via oral mucosal routes. [Learn More](https://cedclinic.com/oral-cannabinoid-bioavailability-delivery-absorption/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Can%20Oral%20Mucosal%20Delivery%20Unlock%20Cannabinoid%20Medicine%E2%80%99s%20Potential%3F&url=https%3A%2F%2Fcedclinic.com%2Foral-mucosal-cannabinoid-absorption-potential%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Foral-mucosal-cannabinoid-absorption-potential%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Can%20Oral%20Mucosal%20Delivery%20Unlock%20Cannabinoid%20Medicine%E2%80%99s%20Potential%3F%20https%3A%2F%2Fcedclinic.com%2Foral-mucosal-cannabinoid-absorption-potential%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).